ImmunoGenes can help you develop new antibody based therapeutics, antibody based diagnostics or novel genetically modified animals (mice, rats, rabbits) for pre-clinical studies. ImmunoGenes owns a patented technology, which provides enhanced immune response and thus greater possibility to produce the right antibody, than the usually used techniques. Our team consists of leading experts in the field of transgenesis, and collaborates with some of the leaders in this field- including, but not limited to The Roslin Institute of the University of Edinburgh, INRA-France, LFB-Group and PolyGene AG. Our experienced scientists can also provide professional advice on how to design a project and give complete support for all steps of antibody production under strict confidentiality. We also divided the antibody development schedule into phases and payment stages, enabling aspects of the project scope to be changed in-process. Our company offers interactive transgene design, rapid turnaround time and efficient world-wide delivery. We also provide proven track record with some of the world's leading developers of rabbit and rat models. ImmunoGenes also supplies breeding and genotyping services. The timely creation of such specialized transgenic animals under high quality standards is limited to a selected group of experts and ImmunoGenes being one of them.
Looking for a particular ImmunoGenes employee's phone or email?
The ImmunoGenes annual revenue was $202000 in 2026.
3 people are employed at ImmunoGenes.
The NAICS codes for ImmunoGenes are [54, 54171, 541713, 541, 5417].
The SIC codes for ImmunoGenes are [873, 87].